X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Ebglyss (lebrikizumab) is an approved high-affinity and potent IL-13 inhibitor being studied in adult and adolescent patients 12 years of age and older with moderate-to-severe AD.
Lead Product(s): Lebrikizumab
Therapeutic Area: Dermatology Product Name: Ebglyss
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 10, 2024
Details:
Ebglyss (lebrikizumab) is a monoclonal antibody that binds IL-13 with high affinity to specifically prevent the formation of the IL-13Rα1/IL-4Rα heterodimer complex. It is approved for the treatment of moderate-to-severe atopic dermatitis.
Lead Product(s): Lebrikizumab
Therapeutic Area: Dermatology Product Name: Ebglyss
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 17, 2023
Details:
Ebglyss (lebrikizumab) is an investigational, monoclonal antibody that binds IL-13, and FDA has issued a complete response letter for the lebrikizumab biologic license application (BLA) for the treatment of moderate-to-severe atopic dermatitis (eczema).
Lead Product(s): Lebrikizumab
Therapeutic Area: Dermatology Product Name: Ebglyss
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 02, 2023
Details:
Ebglyss (lebrikizumab) is an investigational, monoclonal antibody that binds IL-13, which is received positive CHMP opinion for moderate-to-severe atopic dermatitis.
Lead Product(s): Lebrikizumab
Therapeutic Area: Dermatology Product Name: Ebglyss
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 15, 2023
Details:
LY3650150 (lebrikizumab) is an investigational high-affinity and potent IL-13 inhibitor being studied in adult and adolescent patients 12 years of age and older with moderate-to-severe AD.
Lead Product(s): Lebrikizumab
Therapeutic Area: Dermatology Product Name: LY3650150
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 01, 2023
Details:
New, late-breaking data show lebrikizumab responders reported long-lasting results at one year of treatment across measures of improvement in skin clearance, itch and disease extent and severity.
Lead Product(s): Lebrikizumab
Therapeutic Area: Dermatology Product Name: LY3650150
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2022
Details:
Lebrikizumab (LY3650150), is a novel, investigational, monoclonal antibody designed to bind IL-13 with high affinity to specifically prevent the formation of the IL-13Rα1/IL-4Rα heterodimer complex and subsequent signaling.
Lead Product(s): Lebrikizumab
Therapeutic Area: Dermatology Product Name: LY3650150
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2022
Details:
Lebrikizumab is a novel, monoclonal antibody (mAb) that binds to the IL-13 protein with high affinity to specifically prevent the formation of IL-13Rα1/IL-4Rα (Type 2 receptor) which blocks downstream signaling through the IL-13 pathway.
Lead Product(s): Lebrikizumab,Corticosteroids
Therapeutic Area: Dermatology Product Name: LY3650150
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 11, 2022
Details:
More than 50 percent of patients with moderate-to-severe atopic dermatitis (AD) experienced at least 75 percent reduction in disease severity (EASI-75) at 16 weeks when receiving lebrikizumab, an investigational IL-13 inhibitor monotherapy.
Lead Product(s): Lebrikizumab
Therapeutic Area: Dermatology Product Name: LY3650150
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 26, 2022
Details:
Safety profile consistent with prior LY3650150 (lebrikizumab) studies met all primary and key secondary endpoints at week16, also significantly improved disease severity when combined with topical corticosteroids in people with moderate-to-severe atopic dermatitis.
Lead Product(s): Lebrikizumab
Therapeutic Area: Dermatology Product Name: LY3650150
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2021
Details:
In the initial 16-week placebo-controlled period of ADvocate 1 and ADvocate 2, the incidence of treatment-emergent adverse events (AEs) and serious AEs among patients treated with lebrikizumab was consistent with that of the previous Phase 2 lebrikizumab study in AD.
Lead Product(s): Lebrikizumab
Therapeutic Area: Dermatology Product Name: LY3650150
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 16, 2021
Details:
In the initial 16-week placebo-controlled period of ADvocate 1 and ADvocate 2, the incidence of treatment-emergent adverse events (AEs) and serious AEs among patients treated with lebrikizumab was consistent with that of the previous Phase 2 lebrikizumab study in AD.
Lead Product(s): Lebrikizumab
Therapeutic Area: Dermatology Product Name: LY3650150
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 16, 2021
Details:
Data from this study suggests that treatment with lebrikizumab provided rapid and clinically meaningful improvements in itch, sleep and overall measures of quality of life.
Lead Product(s): Lebrikizumab
Therapeutic Area: Dermatology Product Name: LY3650150
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2020
Details:
The acquisition of Dermira also expands Lilly's portfolio of marketed dermatology medicines with the addition of QBREXZA® (glycopyrronium).
Lead Product(s): Lebrikizumab
Therapeutic Area: Dermatology Product Name: LY3650150
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: $1,100.0 million Upfront Cash: $1,100.0 million
Deal Type: Acquisition February 20, 2020
Details:
Lilly gets Dermira’s experimental treatment for atopic dermatitis, as well as an approved medicated cloth for excessive armpit sweating.
Lead Product(s): Lebrikizumab
Therapeutic Area: Dermatology Product Name: LY3650150
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: $1,100.0 million Upfront Cash: $1,100.0 million
Deal Type: Acquisition January 10, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
